Immunosuppression risk groups
Synonym(s)
Risk groups for immune suppression
DefinitionThis section has been translated automatically.
Immunosuppression risk groups of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute
Risk group 1 (moderate immunosuppression/deficiency)
- Granulocytopenia <0.5×109/l (<500/µl) up to 10 days (analog leukopenia <1×109/l; <1000/µl) -
- Deficiency of CD4-positive THelfer cells <250/µl (cave: age-appropriate normal values in children); autologous stem cell transplantation up to three months after intensive therapy
- Patients who have more than 1 characteristic of the immunosuppression/deficiency listed under risk group 1 are placed in risk group 2.
Risk group 2 (severe immunosuppression/deficiency)
- Granulocytopenia <0.5×109/l (<500/µl) for more than 10 days (analogous leukopenia <1×109/l; <1000/µl)
- Severe aplastic anemia or macrophage activation syndrome during intensive immunosuppressive therapy
- Allogeneic bone marrow or/and stem cell transplantation up to 6 months after completion of the intensive therapy phase (important: extent of GVHD and persistent iatrogenic immunosuppression) -
- Acute inpatient treatment phase for autologous stem cell transplantation or after transplantation of solid organs (until discharge)
Risk group 3 (very severe immunosuppression/deficiency)
- Allogenic KMT/PBSCT in intensive therapy phase (until engraftment = regeneration of granulopoiesis)
- Severe GVHD grade III or IV under intensive immunosuppression The decision on the assignment to group 3 in patients after allogeneic stem cell transplantation is ultimately made by the treating oncologists in summary of all findings.